MONDAY, March 14, 2022 (HealthDay News)
A lot of COVID medicines have confirmed their mettle in opposition to the “stealth” BA.2 Omicron variant in lab exams, however it’s not clear how efficient they’d be in real-world use, researchers report.
In lab experiments utilizing non-human primate cells, researchers examined seven monoclonal antibodies, three combos of antibodies, and three antiviral therapies in opposition to the BA.2 variant. Most authorized antibody therapies are a mix of various antibodies.
The antiviral therapies remdesivir, Merck’s molnupiravir and the energetic ingredient in Pfizer’s Paxlovid capsule (nirmatrelvir) labored in opposition to the BA.2 variant, in accordance with the research printed March 9 within the New England Journal of Medicine.
According to the findings, the best antibody remedy in opposition to the BA.2 variant was AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), which is authorized within the United States to assist stop COVID an infection in folks weak to extreme illness.
Antibody therapies type Regeneron and GlaxoSmithKline had been more practical in opposition to BA.2 than they’re in opposition to the BA.1 variant, however weren’t as sturdy in opposition to BA.2 as they had been in opposition to earlier variations of the virus.
The researchers additionally discovered that Lilly’s antibody cocktail of etesevimab and bamlanivimab didn’t neutralize the BA.2 virus at frequent dosages.
“The bottom line is we have antibodies that appear to be more effective against BA. 2 compared with BA.1 or BA.1.1. That’s good news, but we don’t know whether we found in the lab translates into clinical settings, ” stated research chief Yoshihiro Kawaoka, a virologist on the School of Veterinary Medicine on the University of Wisconsin-Madison and the University of Tokyo.
“We also tested clinically available antiviral compounds, and they are all highly efficacious,” he added in a University of Wisconsin information launch.
Current COVID therapies are typically much less efficient in opposition to new variants than in opposition to the unique virus as a result of they had been designed and examined in opposition to earlier variations of the virus, the research authors famous.
It takes months to create and check therapies in opposition to new variants of the virus.
SOURCE: University of Wisconsin-Madison, information launch, March 10, 2022
Copyright © 2021 HealthDay. All rights reserved.